In trading on Tuesday, shares of Array Biopharma Inc (NASDAQ:ARRY) crossed above their 200 day moving average of $5.45, changing hands as high as $5.48 per share. Array BioPharma Inc. shares are currently trading up about 4% on the day. The chart below shows the one year performance of ARRY shares, versus its 200 day moving average: Array Biopharma Inc (NASDAQ:ARRY), shares after opening at $4.15 moved to $4.29 on last trade day and at the end of the day closed at $4.25. Company price to sales ratio in past twelve months was calculated as 8.37 and price to cash ratio as 4.45. Array Biopharma Inc (NASDAQ:ARRY), showed a negative weekly performance of 9.57%.
On April 3, 2014, Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), announced that Lexicon management will present at the Needham Healthcare Conference on Tuesday, April 8, 2014 at 9:20 AM EDT in New York City. Lexicon management will provide an overview of Lexicon’s clinical development programs and milestones. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), shares advanced 3.14% in last trading session and ended the day on $1.64. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), return on equity ratio is recorded as -51.30% and its return on assets is -33.50%. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), yearly performance is -23.72%.
In trading on Thursday, shares of Infinity Pharmaceuticals Inc. (NASDAQ:INFI), entered into oversold territory, hitting an RSI reading of 28.1, after changing hands as low as $10.80 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 63.2. A bullish investor could look at INFI’s 28.1 RSI reading as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. Infinity Pharmaceuticals Inc. (NASDAQ:INFI), shares moved down 1.04% in last trading session and was closed at $10.51, while trading in range of $ 10.13 – 10.90. Infinity Pharmaceuticals Inc. (NASDAQ:INFI), year to date (YTD) performance is -23.90%.
On March, 13, 2014, Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, announced financial results for the year ended December 31, 2013, and provided an update on its clinical trials of ThermoDox, Celsion’s proprietary heat-activated liposomal encapsulation of doxorubicin. ThermoDox is being evaluated in a Phase III clinical trial for primary liver cancer and a Phase II clinical trial for recurrent chest wall breast cancer. Celsion Corporation (NASDAQ:CLSN), weekly performance is -3.86%. On last trading day company shares ended up $3.24. Celsion Corporation (NASDAQ:CLSN), distance from 50-day simple moving average (SMA50) is -12.46%. Analysts mean target Price for the company is $7.88.
Leave a Reply